Scott, P. D. (Paul D.), Meng, Bo, Marriott, Anthony C., Easton, A. J. (Andrew J.) and Dimmock, N. J.. (2011) Defective interfering influenza virus confers only short-lived protection against influenza virus disease : evidence for a role for adaptive immunity in DI virus-mediated protection in vivo. Vaccine, Vol.29 (No.38). pp. 6584-6591. ISSN 0264410X

Preview	PDF (Article) WRAP_Scott_0380313-lf-310811-final_scott_et_al_di_virus_scid_mice.pdf - Accepted Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (211Kb)
Preview	PDF (Figure 1) WRAP_Scott_Fig_1_SCID.pdf - Accepted Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (22Kb)
Preview	PDF (Figure 2) WRAP_Scott_Fig_2_SCID.pdf - Accepted Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (16Kb)
Preview	PDF (Figure 3) WRAP_Scott_Fig__3_SCID.pdf - Accepted Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (62Kb)
Preview	PDF (Figure 4) WRAP_Scott_Fig_4_SCID.pdf - Accepted Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (16Kb)

Abstract

We have shown earlier that a single dose of cloned defective interfering (DI) influenza A virus strongly protects mice from disease following a lethal challenge with different subtypes of influenza A virus. These animals suffered no clinical disease but experienced a subclinical infection which rendered them immune to reinfection with the same challenge virus. However, little is known about how DI virus achieves such protection. Here we investigated the role of adaptive immunity in DI virus-mediated protection using severe-combined immunodeficient (SCID) mice, which lack competence in both B- and T-cell compartments but retain NK cell activity. SCID mice which were treated with DI virus and infected with influenza virus initially remained completely well, while infected litter mates that received UV-inactivated DI virus became seriously ill and died. However, after 10 days of good health, the DI virus-protected SCID mice developed a clinical disease that was similar, but not completely identical, to the acute influenza disease. Disease was delayed longer by a higher dose of DI virus. We excluded the possibilities that the DI virus load in the lungs had declined, that the DI RNA sequence had changed so that it no longer interfered with the infectious genome, or that infectious virus had become resistant to the DI virus. These data show that while DI virus provides full protection from the acute disease in the absence of adaptive immunity, that same immunity is essential for clearing the infection. This indicates that the conventional view that DI virus-induced protection is mediated solely by competition for replication with the challenge virus is incorrect for influenza virus.

Item Type:	Journal Article
Subjects:	Q Science > QL Zoology
Divisions:	Faculty of Science > Life Sciences (2010- )
Library of Congress Subject Headings (LCSH):	Influenza -- Immunological aspects, Mice -- Immunology, Antiviral agents
Journal or Publication Title:	Vaccine
Publisher:	Elsevier BV
ISSN:	0264410X
Date:	2 September 2011
Volume:	Vol.29
Number:	No.38
Page Range:	pp. 6584-6591
Identification Number:	10.1016/j.vaccine.2011.06.114
Status:	Peer Reviewed
Access rights to Published version:	Restricted or Subscription Access
Funder:	Wellcome Trust (London, England), Medical Research Council (Great Britain) (MRC), Mercia Spinner
References:	[1] Holland JJ. Defective viral genomes. In: Fields BN, Knipe DM, editors. Virol. 2nd ed. New York: Raven Press, 1990: 151-65. [2] Holland JJ. Generation and replication of defective viral genomes. In: Fields BN, Knipe DM, editors. Virol. 2nd ed. New York: Raven Press, 1990: 77-99. [3] Huang AS, Baltimore D. Defective viral particles and viral disease processes. Nature (Lond) 1970;226:325-7. [4] Perrault J. Origin and replication of defective interfering particles. Curr Topics Microbiol Immunol 1981;93:151-207. [5] Nayak DP, Chambers TM, Akkina RM. Structure of defective-interfering RNAs of influenza virus and their role in interference. In: Krug RM, editor. The Influenza Viruses. New York: Plenum Press, 1989: 269-317. [6] Roux L, Simon AE, Holland JJ. Effects of defective interfering viruses on viral replication and pathogenesis in vitro and in vivo. Adv Virus Res 1991;40:181-211. [7] Marriott AC, Dimmock NJ. Defective interfering viruses and their potential as antiviral agents. Rev Med Virol 2010;20:51-62. [8] Barrett ADT, Dimmock NJ. Defective interfering viruses and infections of animals. Curr Topics Microbiol Immunol 1986;128:55-84. [9] Dimmock NJ. The biological significance of defective interfering viruses. Rev Med Virol 1991;1:165-76. [10] Dimmock NJ. Antiviral activity of defective interfering influenza virus in vivo. In: Myint S, Taylor-Robinson D, editors. Viral and Other Infections of the Respiratory Tract. London: Chapman and Hall, 1996: 421-45. [11] von Magnus P. Incomplete forms of influenza virus. Adv Virus Res 1954;21:59-79. [12] Nayak DP. Influenza virus defective interfering particles. Ann Rev Microbiol 1980;34:619-44. [13] Nayak DP, Chambers TM, Akkina RK. Defective-interfering (DI) RNAs of influenza viruses: origin, structure, expression and interference. Curr Topics Microbiol Immunol 1985;114:103-51. [14] Duhaut SD, Dimmock NJ. Heterologous protection against a lethal human H1N1 influenza virus infection of mice by a H3N8 equine defective interfering virus: comparison of defective RNA sequences isolated from the DI inoculum and mouse lung. Virol 1998;248:241-53. [15] Duhaut S, Dimmock NJ. Approximately 150 nt from the 5' end of an influenza A virus segment 1 defective virion RNA are needed for genome stability during passage of defective virus in infected cells. Virol 2000;275:278-85. [16] Duhaut SD, Dimmock NJ. Defective segment 1 RNAs that interfere with the production of infectious influenza virus require at least 150 nucleotides of 5' sequence: evidence from a plasmid-driven system. J Gen Virol 2002;83:403-11. [17] Duhaut SD, Dimmock NJ. Defective influenza A virus generated entirely from plasmids: its RNA is expressed in infected mouse lung and modulates disease. J Virol Meth 2003;108:75-82. [18] Dimmock NJ, Rainsford EW, Scott PD, Marriott AC. Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral. J Virol 2008;82:8570-8. [19] McLain L, Morgan DJ, Dimmock NJ. Protection of mice from lethal influenza by defective interfering virus: T cell responses. J Gen Virol 1992;73:375-81. [20] McLain L, Dimmock NJ. Protection of mice from lethal influenza by adoptive transfer of non-neutralizing haemagglutination-inhibiting IgG obtained from the lungs of infected animals treated with defective-interfering virus. J Gen Virol 1989;70:2615-24. [21] Morgan DJ, Dimmock NJ. Defective interfering virus inhibits immunopathological effects of infectious virus in the mouse. J Virol 1992;66:1188-92. [22] Morgan DJ, McLain L, Dimmock NJ. Protection of three strains of mice against lethal influenza in vivo by defective interfering virus. Virus Res 1993;29:179-93. [23] McLain L, Dimmock NJ. An influenza haemagglutinin-specific IgG enhances class I MHC-restricted CTL killing in vitro. Immunol 1991;73:12-8. [24] McLain L, Dimmock NJ. A monoclonal antibody produced during infection which recognizes an epitope of influenza hemagglutinin only in the context of H-2k MHC class I antigen. J Immunol 1993;150:3421-6. [25] Dimmock NJ, Beck S, McLain L. Protection of mice from lethal influenza: evidence that defective interfering virus modulates the immune response and not virus multiplication. J Gen Virol 1986;67:839-50. [26] Albert SE, McKerlie C, Pester A, Edgell B-J, Carlyle J, Petric M, et al. Time-dependent induction of protective anti-influenza immune responses in human peripheral blood lymphocyte/SCID mice. J Immunol 1997;159:1393-403. [27] Bot A, Reichlin A, Isobe H, Bot S, Schulman J, Yokoyama WM, et al. Cellular mechanisms involved in protection and recovery from influenza virus infection in immunodeficient mice. J Virol 1996;70:5668-72. [28] Bunting KD, Flynn, K. J., Riberdy, J. M., Doherty, P. C., and Sorrentino, B. P. . Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency. Proc Natl Acad Sci USA 1999;96:232-7. [29] Ison MG, Mishin VP, Braciale TJ, Hayden FG, Gubareva LV. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J Infect Dis 2006;193:765-72. [30] Mozdzanowska K, Feng, J., and Gerhard, W. Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice. J Virol 2003;77:8322-8. [31] Zharikova D, Mozdzanowska, K., Feng, J. Q., Zhang, M. X., and Gerhard, W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 2005;79:6644-54. [32] Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate by plasmid-based reverse genetics. Virol 2003;305:192-200. [33] Noble S, Dimmock NJ. Defective interfering type A equine influenza virus (H3N8) protects mice from morbidity and mortality caused by homologous and heterologous subtypes of type A influenza virus. J Gen Virol 1994;75:3485-91. [34] Noble S, McLain L, Dimmock NJ. Interfering vaccine: a novel antiviral that converts a potentially virulent infection into one that is subclinical and immunizing. Vaccine 2004;22:3018-25. [35] Di Trani L, Bedini B, Donatelli I, Campitelli L, Chiappini B, De Marco MA, et al. A sensitive one-step real-time PCR for detection of avian influenza viruses using a MGB probe and an internal positive control. BMC Infect Dis 2006;6:87-94. [36] Smith GL, Hay AJ. Replication of the influenza virus genome. Virol 1982;118:96-108. [37] Hatada E, Hasegawa M, Mukaigawa J, Shimizu K, Fukuda R. Control of influenza virus gene expresssion: quantitative analysis of each viral RNA species in infected cells. J Biochem 1989;105:537-46. [38] Weiss B, Schlesinger S. Defective interfering particles of Sindbis virus do not interfere with the homologous virus obtained from persistently infected BHK cells but do interfere with Semliki Forest virus. J Virol 1981;37:840-4. [39] Rowlands DJ, Grabau E, Spindler K, Jones C, Semler B, Holland JJ. Virus protein changes and RNA termini alterations evolving during persistent infection. Cell 1980;19:871-80. [40] Holland JJ, Spindler K, Grabau E, Semler B, Jones C, Horodyski F, et al. Viral mutation in persistent infection. In: Fields BN, Jaenisch R, Fox CF, editors. ICN-UCLA Symposium on Molecular and Cellular Biology. Animal Virus Genetics ed. New York: Academic Press, 1980: 695-709. [41] Giachetti C, Holland JJ. Altered replicase specificity is responsible for resistance to defective interfering particle interference of an Sdi- mutant of vesicular stomatitis virus. J Virol 1988;62:3614-21. [42] DePolo N, Giachetti C, Holland JJ. Continuing coevolution of virus and defective interfering particles and of viral genome sequences during undiluted passages: virus mutants exhibiting nearly complete resistance to formerly dominant defective interfering particles. J Virol 1987;61:454-64. [43] Horodyski FM, Holland JJ. Viruses isolated from cells persistently infected with vesicular stomatitis virus show altered interactions with defective interfering particles. J Virol 1980;36:627-31. [44] Weiss B, Levis R, Schlesinger S. Evolution of virus and defective-interfering RNAs in BHK cells persistently infected with Sindbis virus. J Virol 1983;48:676-84. [45] Doherty PC, Allan, W., Eichelberger, M., and Carding, S. R. Roles of alpha/beta and gamma/delta T cell subsets in viral immunity. Ann Rev Immunol 1992;10:123-51. [46] Gerhard W, Mozdanowska, K., Furchner, M., Washko, G., and Maiese, K. Role of the B-cell response in the recovery of mice from primary influenza virus infection. Immunol Revs 1997;159:95-103. [47] Wright PF, and Webster, R. G. Orthomyxoviruses. In: Knipe D, Howley PM, editors. Fields Virology. 4 ed. Philadelphia, PA: Lippincott, Williams, and Wilkins, 2001: 1533-79. [48] Noda T, Kawaoka Y. Structure of influenza virus ribonucleoprotein complexes and their packaging into virions. Rev Med Virol 2010;20:380-91. [49] Easton AJ, Scott PD, Edworthy NL, Meng B, Marriott AC, Dimmock NJ. A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo. Vaccine 2011;29:2777-84.
URI:	http://wrap.warwick.ac.uk/id/eprint/37169

Request changes to a record

Actions (login required)

View Item